Skip to main content
Loading market data...
ETF Nasdaq USD

Defiance Autism Impact ETF ASD

Issuer: Defiance SEC registrant: ETF Series Solutions Equity · Global
Last price 27.04 USD Change: Up +0.37 Percent change: Up +1.39%

Source: Yahoo Finance (opens in a new tab) Observed · 1 day ago Quotes may be delayed

Expense ratio
0.79%
Prospectus 28 May 2026
Net assets
$1.4M
As of 30 Jun 2026
Holdings
39
As of 30 Jun 2026
12-month distribution yield
0.03%
Quarterly
Asset class
Equity
From holdings

Defiance Autism Impact ETF (ASD) is an exchange-traded fund listed on the Nasdaq in the United States, issued by Defiance. Its category is Equity · Global (equity). Its last price was US$27.04 on 20 Oct 2026. Its expense ratio is 0.79% a year, from its prospectus dated 28 May 2026. It reported net assets of US$1.35 million as of 30 Jun 2026. Its latest holdings report lists 39 holdings as of 30 Jun 2026. Over the last 12 months it paid distributions of US$0.0080 a unit, a 12-month distribution yield of 0.03%, paid quarterly.

General information only: nothing on TakeProfits takes into account your objectives, financial situation or needs, and it isn't personal financial advice or a recommendation to buy or sell anything. Consider whether it suits you and get advice from a licensed adviser before acting. Market data may be delayed and comes from third-party sources.

Fees

Total annual operating expenses (gross)
0.79%
Net, after fee waivers or reimbursements
No waiver stated
Management fee
0.79%
Prospectus date
28 May 2026
Filed with the SEC
28 May 2026

Size and reporting

Net assets
$1,351,025
Total assets
$1,352,088
Holdings as of
30 Jun 2026
Report made public
28 Aug 2026 (59 days after the month end)

Net assets are for the whole fund series, which for some funds (Vanguard's, for example) also includes mutual fund share classes.

Top holdings

Largest 25 of 39 positions, as of 30 Jun 2026. Weight is the percent of net assets the fund reported.

ASD top holdings as of 30 Jun 2026
# Holding Identifier Weight Value (USD) Type Country Currency
1 Definium Therapeutics Inc CA24477V1058 4.77% $64K Equity (common) United States USD
2 Neuren Pharmaceuticals Ltd NZNEUE0001S8 3.23% $44K Equity (common) Australia AUD
3 LifeStance Health Group Inc US53228F1012 3.04% $41K Equity (common) United States USD
4 Otsuka Holdings Co Ltd JP3188220002 2.95% $40K Equity (common) Japan JPY
5 Acadia Healthcare Co Inc US00404A1097 2.90% $39K Equity (common) United States USD
6 ACADIA Pharmaceuticals Inc US0042251084 2.89% $39K Equity (common) United States USD
7 MapLight Therapeutics Inc US56565P1030 2.89% $39K Equity (common) United States USD
8 AbbVie Inc US00287Y1091 2.72% $37K Equity (common) United States USD
9 BrightSpring Health Services I BrightSpring Health Services Inc US10950A1060 2.70% $37K Equity (common) United States USD
10 Revvity Inc US7140461093 2.68% $36K Equity (common) United States USD
11 Bright Horizons Family Solutio Bright Horizons Family Solutions Inc US1091941005 2.65% $36K Equity (common) United States USD
12 Medicover AB SE0009778848 2.63% $36K Equity (common) Sweden SEK
13 Ipsen SA FR0010259150 2.60% $35K Equity (common) France EUR
14 Sumitomo Pharma Co Ltd JP3495000006 2.60% $35K Equity (common) Japan JPY
15 Johnson & Johnson US4781601046 2.59% $35K Equity (common) United States USD
16 Brainsway Ltd US10501L1061 2.58% $35K Equity (common) Israel USD
17 Pearson PLC GB0006776081 2.56% $35K Equity (common) United Kingdom GBP
18 Anavex Life Sciences Corp US0327973006 2.53% $34K Equity (common) United States USD
19 Novartis AG CH0012005267 2.53% $34K Equity (common) Switzerland CHF
20 Life Healthcare Group Holdings Life Healthcare Group Holdings Ltd ZAE000145892 2.52% $34K Equity (common) South Africa ZAR
21 BioMarin Pharmaceutical Inc US09061G1013 2.52% $34K Equity (common) United States USD
22 KPJ Healthcare Bhd MYL5878OO003 2.51% $34K Equity (common) Malaysia MYR
23 Repligen Corp US7599161095 2.50% $34K Equity (common) United States USD
24 Roche Holding AG CH1499059983 2.50% $34K Equity (common) Switzerland CHF
25 Supernus Pharmaceuticals Inc US8684591089 2.50% $34K Equity (common) United States USD

Breakdowns

Sums of reported weights over every position in the report. Totals can differ from 100% because of derivatives, borrowing and cash.

Asset type

Asset type by weight
TypeWeightBar
Equity (common) 99.83%
Short-term investment vehicles (cash funds) 0.21%

Country

Country by weight
CountryWeightBar
United States 56.57%
Japan 10.18%
Switzerland 5.04%
United Kingdom 5.02%
Israel 4.93%
Australia 3.23%
Sweden 2.63%
France 2.60%
South Africa 2.52%
Malaysia 2.51%
Ireland 2.50%
Denmark 2.29%

Currency exposure

Currency exposure by weight
CurrencyWeightBar
US dollar (USD) 61.65%
Japanese yen (JPY) 10.18%
Swiss franc (CHF) 5.04%
British pound (GBP) 5.02%
Australian dollar (AUD) 3.23%
Swedish krona (SEK) 2.63%
Euro (EUR) 2.60%
South African rand (ZAR) 2.52%
Malaysian ringgit (MYR) 2.51%
Israeli shekel (ILS) 2.35%
Danish krone (DKK) 2.29%

Sector

Sector weights for holdings matched to listed stocks
SectorWeightBar
Health Care 25.64%
Real Estate 6.79%
Industrials 2.68%
Consumer Discretionary 2.65%

Source: SEC Form N-PORT (opens in a new tab) Holdings as of

Distributions

Paid in the last 12 months
$0.0080
2 payments per unit
12-month yield
0.03%
Distributions only, not total return
Frequency
Quarterly
From the gaps between ex-dates
Latest ex-date
23 Sep 2026

12-month yield = distributions per unit with an ex-date in the last 12 months ($0.0080) ÷ latest price ($27.04) × 100 = 0.03%. It looks back, so it is not a forecast; special distributions in the window are included.

Why a distribution yield is not the fund's return: yield vs total return

Distribution history table (2 payments)
ASD distributions per unit by ex-date
Ex-dateAmount per unit
23 Sep 2026$0.0020
24 Jun 2026$0.0060

Filings and sources

Compare with

Largest funds in the same category:

Up to four symbols separated by commas. ASX funds end in .AX, for example IVV.AX.

How ETF overlap is measured, with a worked example

IMPORTANT FINANCIAL DISCLAIMER: The information provided on this platform is for educational and informational purposes only and should not be construed as investment advice. All investments involve risk, including potential loss of principal. Past performance does not guarantee future results. Take Profits is not a registered investment advisor and does not provide personalized investment advice. Users should conduct their own research and consult with qualified financial professionals before making investment decisions. Market data may be delayed and is provided by third-party sources.

Catalyst evidence

Loading…

Loading evidence…

Supporting sources

    Skip to main content

    All resources and tools

    Market ticker

    Markets

    Research

    Tools

    My investments

    Account

    Region and currency

    Colour theme